Get started
Author

Clarisse Lopes de Castro Lobo

Observed names: C Lopes de Castro Lobo, C. Lobo, C.L. Lobo, Clarisse L. Lobo, Clarisse Lobo, Clarisse Lopes de Castro Lobo, MD, Clarisse Lopes de Castro Lobo<sup></sup>, Clarisse de Castro Lobo, Lobo, Clarisse Lopes de Castro
Institution: Hemorio
ORCID: 0000-0002-4262-5792
Observed ORCIDs: 0000-0002-4262-5792, 0009-0003-8954-1902
OpenAlex ID: A5005004912
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
2010 · Giuseppe Saglio, Dong-Wook Kim, et al. · New England Journal of Medicine · 1,691
PDF
The effect of hydroxcarbamide therapy on survival of children with sickle cell disease
2013 · Clarisse Lopes de Castro Lobo, Jorge F. C. Pinto, et al. · British Journal of Haematology · 167
PDF
Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
2020 · Rodolfo D. Cançado, Aderson da Silva Araújo, et al. · Hematology Transfusion and Cell Therapy · 71
PDF
Newborn screening program for hemoglobinopathies in Rio de Janeiro, Brazil
2013 · Clarisse Lopes de Castro Lobo, Samir K. Ballas, et al. · Pediatric Blood & Cancer · 70
Clinical and genetic ancestry profile of a large multi‐centre sickle cell disease cohort in Brazil
2018 · Anna B. F. Carneiro‐Proietti, Shannon Kelly, et al. · British Journal of Haematology · 69
PDF
Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia
2011 · Danilo Grünig Humberto Silva, Edis Belini Junior, et al. · Blood Cells Molecules and Diseases · 64
Mortality in children, adolescents and adults with sickle cell anemia in Rio de Janeiro, Brazil
2017 · Clarisse Lopes de Castro Lobo, Emilia Matos do Nascimento, et al. · Hematology Transfusion and Cell Therapy · 62
PDF
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
2014 · T. P. Hughes, A. Hochhaus, et al. · Haematologica · 49
Crises dolorosas na doença falciforme
2007 · Clarisse Lobo, Vera Neves Marra, et al. · Revista Brasileira de Hematologia e Hemoterapia · 48
PDF
Triagem neonatal para hemoglobinopatias no Rio de Janeiro, Brasil
2003 · Clarisse Lopes de Castro Lobo, Leíse Marcelo Bueno, et al. · Revista Panamericana de Salud Pública · 43
PDF
ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
2010 · Timothy P. Hughes, Andreas Hochhaus, et al. · Blood · 42
Genomic and epidemiological characterisation of a dengue virus outbreak among blood donors in Brazil
2017 · Nuno R. Faria, Antonio Charlys da Costa, et al. · Scientific Reports · 41
PDF
The influence of hydroxyurea on oxidative stress in sickle cell anemia
2012 · Lidiane de Souza Torres<sup></sup>, Danilo Grünig Humberto da Silva<sup></sup>, et al. · Revista Brasileira de Hematologia e Hemoterapia · 40
Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial
2021 · James F. Casella, Bruce A. Barton, et al. · JAMA · 39
PDF
Tratamento da anemia ferropriva com ferro por via oral
2010 · Rodolfo D. Cançado, Clarisse Lobo, et al. · Revista Brasileira de Hematologia e Hemoterapia · 37
PDF
Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: Results From the International Randomized Phase III ENESTnd Trial
2009 · Giuseppe Saglio, Dong-Wook Kim, et al. · Blood · 36
Protocolo clínico e diretrizes terapêuticas para uso de hidroxiureia na doença falciforme
2009 · Rodolfo D. Cançado, Clarisse Lobo, et al. · Revista Brasileira de Hematologia e Hemoterapia · 35
PDF
Severity of Brazilian sickle cell disease patients: Severity scores and feasibility of the Bayesian network model use
2015 · Edis Belini Junior, Danilo Grünig Humberto Silva, et al. · Blood Cells Molecules and Diseases · 34
Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia
2013 · Danilo Grunig Humberto Silva, Edis Belini Junior, et al. · BMC Medical Genetics · 30
PDF
Case series of octogenarians with sickle cell disease
2016 · Samir K. Ballas, E. Dianne Pulte, et al. · Blood · 29
ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).
2014 · Richard A. Larson, Dong-Wook Kim, et al. · Journal of Clinical Oncology · 29
Brazilian Guidelines for transcranial doppler in children and adolescents with sickle cell disease
2010 · Clarisse Lopes de Castro Lobo, Rodolfo Delfini Cançado, et al. · Revista Brasileira de Hematologia e Hemoterapia · 27
Deep venous thrombosis in children with sickle cell disease
2015 · Tiago de Oliveira Boechat, Emilia Matos do Nascimento, et al. · Pediatric Blood & Cancer · 23
Brazilian Association of Thalassemia protocol for iron chelation therapy in patients under regular transfusion
2013 · Monica Pinheiro de Almeida Veríssimo, Sandra Regina Loggetto, et al. · Revista Brasileira de Hematologia e Hemoterapia · 22
Estimated mortality rates of individuals with sickle cell disease in Brazil: real-world evidence
2023 · Rodolfo Delfini Cançado, Fernando Ferreira Costa, et al. · Blood Advances · 21
Works count: 92
Citation count: 3,137
H-index: 23
I10-index: 39
Year
Topic
Type